Pralatrexate (Folotyn, Allos) has been approved as the first agent to treat peripheral T-cell lymphoma (PTCL), often an aggressive type of non-Hodgkin’s lymphoma. Pralatrexate was designated as an orphan drug under the agency’s accelerated approval process.

Read the rest of this entry »